Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.

Abstract: In part, the present disclosure relates methods for treating, preventing, or reducing the severity of a myeloproliferative disorder (e.g., polycythemia vera, essential thrombocythemia, and myelofibrosis) or one or more complications of a myeloproliferative disorder. The present disclosure further relates methods for treating, preventing, or reducing the severity of a Janus kinase-associated disorder or one or more complications of a Janus kinase-associated disorder. In certain aspects the disclosure provides T?RII antagonists for treating, preventing, or reducing the severity of a myeloproliferative disorder (e.g., polycythemia vera, essential thrombocythemia, and myelofibrosis) or a Janus kinase-associated disorder or one or more complications of a myeloproliferative disorder or a Janus kinase-associated disorder.

Abstract: In certain aspects, the present disclosure relates to T?RII fusion polypeptides comprising a heterologous portion and a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF? associated disorders.

Abstract: In part, the present disclosure relates methods for treating, preventing, or reducing the progression rate and/or severity of myelofibrosis or one or more complications of myelofibrosis (extramedullary hematopoiesis, splenomegaly, anemia, and fibrosis). In certain aspects, the disclosure provides ActRIIB antagonists for use in treating, preventing, or reducing the progression rate and/or severity of one or more complications associated with Janus kinase inhibitor therapy in a patient (e.g., anemia).

Abstract: A system (100) for manufacturing an extrudate (10), such as a honeycomb body, is provided. The system comprises an extruder (102). The extruder is configured to form an extrudate from a wet mixture, such as a ceramic forming mixture. The system further comprises a radiative heat assembly (104). The radiative heat assembly is configured to heat the extrudate. The radiative heat assembly comprises one or more IR light sources (112). The one or more IR light sources are arranged as one or more rings around the extrudate. The system further comprises a differential pressure assembly (108). The differential pressure assembly is configured to remove at least a portion of water vapor from around the extrudate. The differential pressure assembly can direct an air flow out of a chamber (136) formed by a housing (132) surrounding the radiative heat assembly. Alternatively, the differential pressure assembly can direct an air flow into the chamber.

Abstract: The present disclosure pertains to a system and a method that enables primary secondary routing in order to optimise data path of the information exchanged between various network functions, thereby avoid cases of data hampering, data loss, and data misplacement. A request is obtained at 702, and then, it is checked at 704, whether any/at least one endpoint is active. If all/some of the end points are found to be active, then all the traffic is routed to Primary Cluster 710, and the obtained request is transmitted and distributed over all the endpoints of the Primary Cluster 710. However, in case, it is found that no endpoint is active, then all the traffic can be routed to Secondary Cluster 720, and the obtained request is transmitted and distributed over the active endpoints of the Secondary Cluster 720.

Abstract: In certain aspects, the disclosure provides multispecific binders (e.g., ActRIIB:T?RII heteromultimers comprising an ActRIIB polypeptide and a T?RII polypeptide). In some embodiments, the disclosure provides for novel binders comprising a T?RII polypeptide and a heterologous portion. The disclosure further provides that such multispecific binders (e.g., ActRIIB:T?RII heteromultimer) may be used to treat various disorders or conditions.

Abstract: Disclosed herein include compositions and kits comprising recombinant adeno-associated viruses (rAAVs) with tropisms to the central nervous system, the peripheral nervous system, and/or the lung, with increased specificity and transduction efficiency. Also described include methods of treating various diseases and conditions using the rAAVs.

Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and antibodies that inhibit receptor-ligand interaction.

Abstract: This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain aspects the ActRII-binding proteins inhibit, or antagonize, ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated muscle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.

Abstract: In some aspects, the invention teaches pharmaceutical compositions that include a TGF-? ligand trap, and methods of using a TGF-? ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-? ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-? signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-? ligand trap to reduce right ventricular systolic pressure in a subject.

Abstract: In some aspects, the disclosure relates to compositions and methods comprising ActRII antagonists to treat, prevent, or reduce the progression rate and/or severity of a renal disease or condition, particularly treating, preventing or reducing the progression rate and/or severity of one or more renal diseases or conditions, particularly treating, preventing or reducing the progression rate and/or severity of one or more renal-associated complications. The disclosure also provides methods of using an ActRII antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, Alport syndrome, focal segmental glomerulosclerosis (FSGS), polycystic kidney disease, and/or chronic kidney disease.

Abstract: The present disclosure facilitates to connect network elements through internetwork communication links that enable routing with active and standby instances. For both the ingress/egress active-active routing, when a request to route traffic is obtained, it is determined whether any/at least one of an endpoint are active. If all the end points are found to be active, then the traffic may be equally divided amongst the nodes present within the active cluster. However, if some of the end points are found to be active, while others are found to be not active, then the traffic is equally divided amongst the active nodes present within the active cluster.

Abstract: The present invention relates to a novel integrated process to extract and purify levulinic acid (LA) produced from the technical lignin waste (2-G residue) generated after second generation (2-G) ethanol production from biomass. In this process, liquid-liquid extraction was carried out using fusel oil as an organic extractant to yield a LA rich organic phase and an acidic aqueous phase (raffinate). In addition, selected amines improved the LA yields by acting synergistically. Further fractional distillation was carried out to purify LA. The acidic raffinate is recycled back to the reaction in multiple times, which reduce the use of additional catalyst and make the overall process cost effective. The process is very simple and suitable to remove any colour and humins (soluble tar), which would otherwise form a problem in subsequent process step, particularly in distillation. At optimized process conditions 95% LA is recovered with 98% purity.

Abstract: The present invention provides an improved process for high titer lactic acid production using simultaneous saccharification and co-fermentation process using acid treated lignocellulosic biomass. The process comprises of pretreating lignocellulosic biomass comprising C5 and C6 sugars with dilute acid and superheated steam at a temperature ranging from 150-210° C.; neutralizing the pretreated lignocellulosic biomass of step (i) with NaOH pellets; and adding cellulase enzyme in the range of 1.5 to 10 FPU/g, bacteria, nutrients and buffering agent to the neutralized slurry obtained in step (ii) for hydrolysis and co-fermentation of C5 and C6 sugars at a temperature ranging from 40-45° C. for a period of 120-144 hours to obtain lactic acid. The process of the present invention requires simple nutrients and results in high titer lactic acid production within shortest duration of time.

Abstract: In certain aspects, the disclosure provides multispecific binders (e.g., ActRIIA:T?RII heteromultimers comprising an ActRIIA polypeptide and a T?RII polypeptide). The disclosure further provides that such multispecific binders (e.g., ActRIIA:T?RII heteromultimer) may be used to treat various disorders or conditions.

Abstract: An oscillator includes first and second comparators, a first impedance network having a first trim element therein, and a second impedance network having a second trim element therein. The first impedance network is electrically connected to a first input terminal of the first comparator, and the second impedance network is electrically connected to a first input terminal of the second comparator. The first and second impedance networks are configured to cause an improvement in common mode variation within the first and second comparators, in response to trimming of at least one of the first and second trim elements.

Abstract: Embodiments herein disclose a compensation circuit including an OPAMP having an input connected to a node between one end of a first resistor and a drain of a first PMOS. A fifth PMOS includes a drain connected to a drain of a second NMOS and a gate of sixth PMOS. A gate of second NMOS is connected to a node between a drain of fourth PMOS and one end of third resistor. The sixth PMOS includes a drain connected to one end of fifth resistor and another end of fifth resistor connected to a node between a gate of third NMOS and a gate of a fourth NMOS. A seventh PMOS includes a drain connected to a node between another end of the second resistor and third diode.

Abstract: The present disclosure relates to a charge pump circuit with a six-phase clock. The charge pump circuit comprises a six-phase clock circuit and a gate boosting charge pump configured to receive a plurality of clock signals from the six-phase clock circuit. The six-phase clock circuit includes provides a first clock signal, a second clock signal, a third clock signal, a fourth clock signal, a fifth clock signal, and a sixth clock signal. The gate boosting charge pump is configured to enable a charge-sharing operation to share the stored amount of charges between a plurality of parasitic capacitors. The six-phase clock circuit is configured to provide a dead time between each of the first, second, third, fourth, fifth and sixth clock.

Abstract: In certain aspects, the disclosure provides ALK7 antagonists. In certain aspects, these alk7 antagonists are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7 antagonists can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof. In certain aspects, these ALK7 antagonists can be used to treat or prevent cancer.